Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA380394
Max Phase: Preclinical
Molecular Formula: C17H17NO4S
Molecular Weight: 331.39
Molecule Type: Small molecule
Associated Items:
ID: ALA380394
Max Phase: Preclinical
Molecular Formula: C17H17NO4S
Molecular Weight: 331.39
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: O=C(O)c1c(NS(=O)(=O)c2ccccc2)ccc2c1CCCC2
Standard InChI: InChI=1S/C17H17NO4S/c19-17(20)16-14-9-5-4-6-12(14)10-11-15(16)18-23(21,22)13-7-2-1-3-8-13/h1-3,7-8,10-11,18H,4-6,9H2,(H,19,20)
Standard InChI Key: RRXVUYHFDBLTEL-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 331.39 | Molecular Weight (Monoisotopic): 331.0878 | AlogP: 3.06 | #Rotatable Bonds: 4 |
Polar Surface Area: 83.47 | Molecular Species: ACID | HBA: 3 | HBD: 2 |
#RO5 Violations: 0 | HBA (Lipinski): 5 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 4.07 | CX Basic pKa: | CX LogP: 3.57 | CX LogD: 0.39 |
Aromatic Rings: 2 | Heavy Atoms: 23 | QED Weighted: 0.90 | Np Likeness Score: -0.89 |
1. Sheppard GS, Wang J, Kawai M, Fidanze SD, BaMaung NY, Erickson SA, Barnes DM, Tedrow JS, Kolaczkowski L, Vasudevan A, Park DC, Wang GT, Sanders WJ, Mantei RA, Palazzo F, Tucker-Garcia L, Lou P, Zhang Q, Park CH, Kim KH, Petros A, Olejniczak E, Nettesheim D, Hajduk P, Henkin J, Lesniewski R, Davidsen SK, Bell RL.. (2006) Discovery and optimization of anthranilic acid sulfonamides as inhibitors of methionine aminopeptidase-2: a structural basis for the reduction of albumin binding., 49 (13): [PMID:16789740] [10.1021/jm0601001] |
2. Kawai M, BaMaung NY, Fidanze SD, Erickson SA, Tedrow JS, Sanders WJ, Vasudevan A, Park C, Hutchins C, Comess KM, Kalvin D, Wang J, Zhang Q, Lou P, Tucker-Garcia L, Bouska J, Bell RL, Lesniewski R, Henkin J, Sheppard GS.. (2006) Development of sulfonamide compounds as potent methionine aminopeptidase type II inhibitors with antiproliferative properties., 16 (13): [PMID:16632353] [10.1016/j.bmcl.2006.03.085] |
3. Shahlaei M, Sabet R, Ziari MB, Moeinifard B, Fassihi A, Karbakhsh R.. (2010) QSAR study of anthranilic acid sulfonamides as inhibitors of methionine aminopeptidase-2 using LS-SVM and GRNN based on principal components., 45 (10): [PMID:20691509] [10.1016/j.ejmech.2010.07.010] |
Source(1):